生命科学资讯
生物技术与制药领域的最新动态
Summit gets November PDUFA date for its PD-1xVEGF bispecific
Trump looks to raise South Korea levies; Siegfried expands
Agomab anticipates $182M IPO as it builds fibrosis pipeline
AstraZeneca makes $15B bet on China to expand manufacturing and R&D
赛诺菲称其150亿欧元交易预算及研发投入有望缓解Dupixent专利悬崖压力。
Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff
礼来成为旗舰公司Repertoire的新自身免疫合作伙伴。
Flagship's Repertoire gets another autoimmune partner in Lilly
Tenpoint公司获FDA批准用于老花眼滴眼液，并获2.35亿美元投资。
Tenpoint gets FDA nod for presbyopia eye drop and $235M
ChenMed CEO警告老年人慎用GLP-1类药物
ChenMed CEO warns against GLP-1s for seniors
第三轮IRA谈判预计对制药业“可控”
Round three of IRA negotiations is expected to be ‘manageable’ for pharma
口服落健制造商Veradermics拟通过IPO融资1.81亿美元
Oral Rogaine maker Veradermics looks to raise $181M from IPO
FDA请求法院暂停路易斯安那州堕胎药争议。
FDA asks court to pause Louisiana's abortion pill fight
龙沙集团仍计划出售其胶囊与健康配料业务
Lonza still intends to sell its capsules and health ingredients business
龙沙集团仍计划出售其胶囊与健康成分业务——Endpoints新闻
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
梯瓦制药CEO宣布公司已成功转型为生物制药企业。
Teva CEO says it has successfully transitioned into a biopharma company
FDA暂停再生元基因疗法试验，因患者出现脑瘤。
FDA suspends Regenxbio gene therapy trials after patient developed brain tumor
美国卫生与公众服务部拟在特朗普医保计划启动前，为制药商规避反回扣法提供保护。
HHS seeks to protect drugmakers from anti-kickback laws ahead of TrumpRx launch
Eikon计划通过IPO融资2.73亿美元，其研发管线以中国抗癌药物为主导。
Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs
Included Health推出替代性健康计划
Included Health launches alternative health plan
恒瑞医药引领潮流，中国药企志在全球市场。
Hengrui blazes trail as Chinese drugmakers aspire to go multinational